Boston Scientific's Cardio Comeback

The shares got a boost Monday after the company said it had resolved quality problems at a plant that makes heart-monitoring devices

The medical device maker Boston Scientific (BSX) announced Apr. 16 that it resolved quality problems at a facility in St. Paul, Minnesota, which were inherited from Guidant (GDT). The development shows how Boston Scientific CEO James R. Tobin is making headway on the project he took on when buying the company for $27 billion last year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.